Contact Us

BioMARC of Colorado State University performed a pre-approval Inspection for GMP manufacturing of a biologics product.

Fort Collins, CO.  November 11, 2013Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) of Colorado State University (CSU), has recently completed an inspection by the US Food and Drug Administration (FDA) as part of a planned preapproval inspection (PAI) for a biological product license.

This PAI activity by the FDA is the culmination of a successful manufacturing project by BioMARC on behalf of one of their clients.  At the completion of the inspection, Dr. Dennis Pierro, Director of BioMARC, praised his staff for their outstanding efforts and for their seamless and thorough agency interactions as well as their ability to present a GMP facility receiving its first product manufacturing inspection.  Dr. Pierro also commented that “[t]he inspection went very well and I believe the inspection team was very impressed with our thoroughness and attention to detail. Now with this PAI behind us the staff at BioMARC, are dedicated to support the continuous improvement paradigm of cGMP in all future projects”.

Kathleen Delehoy, Senior Associate Vice President for Research at CSU stated, “[t]his first-ever PAI inspection at CSU is a huge accomplishment for the BioMARC team and CSU.  It signifies that BioMARC has a highly accomplished and professional team with a robust Quality System in place.  It also demonstrates that BioMARC is moving in the right direction when it comes to cGMP Manufacturing of Biologic products, in particular the BSL-3 manufacturing.”

ABOUT CSU/BioMARC, 

BioMARC is a nonprofit Contract Manufacturing Organization (CMO) owned and operated by CSU, created to produce biopharmaceutical products for non-clinical, clinical, and commercial use under Biosafety Level 3 (BSL-3) and BSL-2 containment and Select Agent (SA) biosecurity conditions.  In addition to manufacturing and testing services, BioMARC offers product and process development services, which includes the creation of development programs focused on implementation of cGMP regulations and scalability issues. 

BioMARC has expertise in developing and optimizing product manufacturing processes and related tests for therapeutic, vaccines, and diagnostic products.  BioMARC specializes in high containment cGMP manufacturing of biologics from preclinical stages through phase I-III and commercial production and has experience in recombinant botulinum toxins.  Recently, BioMARC’s production areas were inspected by the US-CDC for manufacturing of complex biologics including toxins.

Please visit us at www.biomarc.colostate.edu or contact Patrick Berner at patrick.berner@colostate.edu, (970) 492-4353 for more information.


CONTACT INFORMATION
Dennis Pierro, PhD                                                            
Director                                                                             
dennis.pierro@colostate.edu                                              
(970) 491-8954                                                                   

Patrick Berner                                                         
Manager, Business Development
patrick.berner@clostate.edu
(970) 492-4353

 

 

Contact Information

Dennis Pierro, PhD                                                     
Director                                                                             
dennis.pierro@colostate.edu
(970) 491-8954

Sandy Brown
Contract Supervisor
sandra.brown@colostate.edu
(970) 492-4385
        
Background